Drug Trial Radar · NCT03552276
Long-Term Extension Trial of Tildrakizumab to Prove Its Safety in Subjects With Psoriatic Arthritis Who Have Previously Completed Study With Tildrakizumab.
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
281
Actual
Start
Jul 11, 2018
Primary completion
Sep 18, 2023
Study completion Sep 18, 2023
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries LimitedIndustry
- Sponsor type
- Industry
- First posted
- Jun 11, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A long term study to demonstrate the safety of Tildrakizumab in Subjects with Psoriatic Arthritis who Have Previously Completed Study with Tildrakizumab
Conditions
- Psoriatic Arthritis
Interventions
SUNPG18_07 I (Tildrakizumab 200 mg)Drug
injection
SUNPG18_07 II (Tildrakizumab 100 mg)Drug
injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse EventsTime frame: upto week 208
Locations
66 sites in 8 countries. Site status is shown where the registry gives one.
Site 25
Glendale, Arizona
Site 16
Phoenix, Arizona
Site 14
Denver, Colorado
Site 27
Wichita, Kansas
Site 23
Lexington, Kentucky
Site 20
Monroe, Louisiana
Site 26
Lebanon, New Hampshire
Site 24
Salisbury, North Carolina
Site 19
Cincinnati, Ohio
Site 17
Middleburg Heights, Ohio
Site 18
Memphis, Tennessee
Site 21
Seattle, Washington
Site 22
Spokane, Washington
Site 02
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina
Site 01
Mar del Plata, Buenos Aires, Argentina
Site 03
San Fernando, Buenos Aires, Argentina
Site 32
Budapest, Hungary
Site 34
Budapest, Hungary
Site 33
Kistarcsa, Hungary
Site 11
Chihuahua City, Mexico
Site 08
Cuautitlán Izcalli, Mexico
Site 10
Durango, Mexico
Site 09
Mexico City, Mexico City, Mexico
Site 05
Mexico City, Mexico City, Mexico
Site 06
Monterrey, Nuevo León, Mexico
Site 13
San Luis Potosí City, San Luis Potosí, Mexico
Site 04
San Luis Potosí City, San Luis Potosí, Mexico
Site 07
Culiacán, Sinaloa, Mexico
Site 12
Mérida, Yucatán, Mexico
Site 38
Bialystok, Poland
Site 47
Bytom, Poland
Site 36
Elblag, Poland
Site 39
Katowice, Poland
Site 40
Katowice, Poland
Site 46
Krakow, Poland
Site 43
Lodz, Poland
Site 48
Nowa Sól, Poland
Site 42
Poznan, Poland
Site 53
Sochaczew, Poland
Site 50
Warsaw, Poland
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.